Sanofi and GSK Receive European Commission Approval for Arexvy RSV Vaccine in Adults
The European Commission has approved Arexvy, the RSV vaccine from Sanofi and GSK, for use in adults aged 60 and above. This authorization provides a new preventive option against RSV-related lower respiratory tract disease in older adults across Europe.
- Published date: 29-07-2026 10:02 AM
The European Commission has granted marketing authorization to Sanofi and GSK for Arexvy, a respiratory syncytial virus (RSV) vaccine for adults aged 60 years and older. This approval, announced in June 2024, follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP).
Arexvy is designed to help protect older adults from lower respiratory tract disease caused by RSV, a significant cause of illness and hospitalization in this age group. The approval is based on data from a large-scale clinical trial demonstrating the vaccine's efficacy and safety profile.
This development marks an important step in expanding preventive options for RSV in Europe, where the burden of RSV-related disease among older adults is increasingly recognized. For more information, visit the official press release.
The European Commission has approved Arexvy, the RSV vaccine from Sanofi and GSK, for use in adults aged 60 and above. This authorization provides a new preventive option against RSV-related lower respiratory tract disease in older adults across Europe.